trending Market Intelligence /marketintelligence/en/news-insights/trending/k2022ppQgz4oiadPjXNryg2 content esgSubNav
In This List

Bio-Path Holdings raises $18.5M for working capital

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Bio-Path Holdings raises $18.5M for working capital

Bio-Path Holdings Inc., which develops cancer medicines, closed an $18.5 million registered direct offering.

The Bellaire, Texas-based biotechnology company sold 712,910 common shares at $25.95 apiece.

Bio-Path said it planned to use the net proceeds from the offering for working capital and general corporate purposes.

H.C. Wainwright & Co. was exclusive placement agent for the offering.

Bio-Path's lead product candidate, prexigebersen, is being studied in a phase 2 trial for blood cancers and is in preclinical studies for solid tumors.